FIELD: medicine.
SUBSTANCE: invention refers to medicine, more specifically to clinical pharmacology, and can be used for pharmacological correction of mental disorders. Application of diterpene alkaloid N-oxide of 12-epinapelline as agent possessing anxiolytic activity.
EFFECT: declared invention extends the range of agents having manifested anxiolytic activity, free from side effects of existing tranquilizers.
1 cl, 4 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT POSSESSING ANXIOLYTIC ACTIVITY | 2015 |
|
RU2571286C1 |
| AGENT HAVING ANTICONVULSANT ACTIVITY | 2024 |
|
RU2828199C1 |
| AGENT POSSESSING ANXIOLYTHIC ACTION, ON BASIS OF HYDROGENATED PYRIDO (4,3-b) INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND WAY OF ITS APPLICATION | 2007 |
|
RU2338533C1 |
| MEANS FOR CORRECTION OF CHOLINERGIC DISORDERS OF THE MNESTIC PROCESSES | 2017 |
|
RU2665970C1 |
| CARDIOTROPIC AGENT WITH ANXIOLYTIC AND ANALGESIC PROPERTIES | 2020 |
|
RU2773018C2 |
| NEW N-ARYLSULPHAMIDE DERIVATIVE OF O-BENZOILAMINE-BENZOIC ACID WITH ANXIOLYTIC, ACTOPROTECTIVE AND ANTIDEPRESSANT ACTIVITY | 2016 |
|
RU2643356C2 |
| PHARMACEUTICAL COMPOSITION BASED ON N-BENZYL-N-METHYL-1-PHENYLPYRROLO [1,2-A] PYRAZINE-3-CARBOXAMIDE | 2017 |
|
RU2689396C2 |
| LOW MOLECULAR WEIGHT MIMETIC OF BRAIN NEUROTROPHIC FACTOR WITH ANALGESIC, ANXIOLYTIC AND ANTIADDICTIVE EFFECTS | 2020 |
|
RU2759023C2 |
| QUINAZOLINE DERIVATIVES, POSSESSING ANTIDEPRESSANT, ANXIOLYTIC AND NOOTROPIC ACTIVITY | 2012 |
|
RU2507199C1 |
| MEDICATION, POSSESSING ANXIOLYTIC ACTIVITY | 2013 |
|
RU2519191C1 |
